Yumanity and Merck Ink $500 Million+ Deal for Neurodegenerative Diseases

Yumanity Therapeutics and Merck signed a strategic research and license deal for two Yumanity programs. The two preclinical programs are for amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia (FTLD).